Search clinical trials for: Native Chinese subjects

Total 26832 results

Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Healthy Male Volunteers
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Food Effect Study of Anaprazole in Healthy Chinese Subjects

Healthy Male Volunteers
Ascletis Pharmaceuticals Co., Ltd.

Completed

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Healthy

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Advanced Head, Neck and Chest Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
Bristol-Myers Squibb

Completed

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Autoimmune Diseases

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

Healthy Subjects

China
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects

Healthy Subjects

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Bristol-Myers Squibb

Completed

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

Healthy

China
Bristol-Myers Squibb

Completed

A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

Melanoma

China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

Locally Advanced or Metastatic NSCLC

China
Shanghai University of Traditional Chinese Medicine
RenJi Hospital

Unknown

The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

Healthy Adult Male and Female Volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects

Healthy Adult Subjects

China
GlaxoSmithKline

Completed

Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
GlaxoSmithKline

Completed

Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects

Anxiety Disorders

China
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

Diabetes Mellitus, Type 2 | Diabetes

Hong Kong, China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects

Healthy Subject

China
Peking University Cancer Hospital & Institute
Peking University First Hospital; Peking University People's Hospital; Peking... and other collaborators

Unknown

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

MSI-H or dMMR Advanced Solid Tumors

China
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Healthy

China
United Therapeutics

Completed

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy (FREEDOM-EV)

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (TAILOR)

Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Extensive Small Cell Lung Cancer

China
RemeGen Co., Ltd.

Completed

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Healthy

China
Nuance Pharma (shanghai) Co., Ltd

Completed

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

Healthy Subjects

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Anlotinib in Subjects With Advanced Malignancy

Advanced Malignancy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
AstraZeneca

Completed

A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

Atherosclerosis

China
Novo Nordisk A/S

Completed

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Celgene

Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Multiple Myeloma

China
Janssen Research & Development, LLC

Completed

Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

China
BeiGene

Completed

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Solid Tumors

China
Beijing Continent Pharmaceutical Co, Ltd.

Completed

Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects

Hydronidone

China
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain

Pain | Cancer

China
GlaxoSmithKline

Completed

Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years

Asthma

China
Polaris Group

Completed

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy (ADI-PEG 20)

Hepatocellular Carcinoma

United States, Korea, Republic of, Taiwan, Italy, United Kingdom, China
AstraZeneca

Completed

Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects

Healthy Subjects

Hong Kong
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

Squamous Non-small Cell Lung Cancer

China
RemeGen Co., Ltd.

Completed

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Advanced Cancer | Urothelial Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China

3

Subscribe